- Home
- SGMO
as 07-26-2024 4:00pm EST
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.
| Founded: | 1995 | Country: | United States |
| Employees: | N/A | City: | RICHMOND |
| Market Cap: | 103.8M | IPO Year: | 2000 |
| Target Price: | $5.17 | AVG Volume (30 days): | 23.7M |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.86 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.29 - $1.48 | Next Earning Date: | 08-06-2024 |
| Revenue: | $18,756,000 | Revenue Growth: | -92.22% |
| Revenue Growth (this year): | -76.18% | Revenue Growth (next year): | 108.99% |
Latest Sangamo Therapeutics Inc. News
SGMO Breaking Stock News: Dive into SGMO Ticker-Specific Updates for Smart Investing
Business Wire
3 days ago
Sangamo Therapeutics Reports on Pfizer’s Announcement of Positive Topline Results From Phase 3 Trial of Hemophilia A Gene Therapy Candidate
Zacks
a month ago
Sarepta Therapeutics (SRPT) Soars 30.1%: Is Further Upside Left in the Stock?
Simply Wall St.
2 months ago
We Think Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) CEO Compensation Package Needs To Be Put Under A Microscope
Simply Wall St.
2 months ago
US$3.50 - That's What Analysts Think Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Is Worth After These Results
Insider Monkey
2 months ago
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q1 2024 Earnings Call Transcript
Simply Wall St.
3 months ago
Sangamo Therapeutics First Quarter 2024 Earnings: US$0.27 loss per share (vs US$0.13 profit in 1Q 2023)
GuruFocus.com
3 months ago
Sangamo Therapeutics Reports Q1 2024 Results: A Deep Dive into Financials and Strategic Highlights
Zacks
3 months ago
Sangamo Therapeutics (SGMO) Reports Q1 Loss, Lags Revenue Estimates
Compare SGMO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SGMO Sangamo Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.